Literature DB >> 19275698

Antiviral treatment of chikungunya virus infection.

Xavier de Lamballerie1, Laetitia Ninove, Rémi N Charrel.   

Abstract

Chikungunya virus is a typical emerging virus which has been responsible for several million cases of human infections since 2004. No antiviral treatment is currently available. The antimalarial chloroquine has been used in the past but recent studies suggest that it is not or poorly active in vivo. A number of tracks are currently under investigation (inhibition of viral enzymes, of virus entry or maturation, enhancement of immunological response) and new animal models have been made available, including a mouse model and a non-human primate model. We review here the main perspectives of chikungunya antiviral treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275698     DOI: 10.2174/187152609787847712

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  21 in total

Review 1.  Hendra and nipah infection: pathology, models and potential therapies.

Authors:  Frederic Vigant; Benhur Lee
Journal:  Infect Disord Drug Targets       Date:  2011-06

2.  Next generation sequencing of DNA-launched Chikungunya vaccine virus.

Authors:  Rachmat Hidajat; Brian Nickols; Naomi Forrester; Irina Tretyakova; Scott Weaver; Peter Pushko
Journal:  Virology       Date:  2016-02-06       Impact factor: 3.616

3.  DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.

Authors:  Irina Tretyakova; Jason Hearn; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

4.  Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression.

Authors:  Parveen Kaur; Meerra Thiruchelvan; Regina Ching Hua Lee; Huixin Chen; Karen Caiyun Chen; Mah Lee Ng; Justin Jang Hann Chu
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

5.  Expression of plasmid-based shRNA against the E1 and nsP1 genes effectively silenced Chikungunya virus replication.

Authors:  Shirley Lam; Karen Caiyun Chen; Mary Mah-Lee Ng; Justin Jang Hann Chu
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

Review 6.  Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia.

Authors:  Laurence Dupuis-Maguiraga; Marion Noret; Sonia Brun; Roger Le Grand; Gabriel Gras; Pierre Roques
Journal:  PLoS Negl Trop Dis       Date:  2012-03-27

Review 7.  Antiviral perspectives for chikungunya virus.

Authors:  Deepti Parashar; Sarah Cherian
Journal:  Biomed Res Int       Date:  2014-05-15       Impact factor: 3.411

8.  A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.

Authors:  Peter B Madrid; Sidharth Chopra; Ian D Manger; Lynne Gilfillan; Tiffany R Keepers; Amy C Shurtleff; Carol E Green; Lalitha V Iyer; Holli Hutcheson Dilks; Robert A Davey; Andrey A Kolokoltsov; Ricardo Carrion; Jean L Patterson; Sina Bavari; Rekha G Panchal; Travis K Warren; Jay B Wells; Walter H Moos; Raelyn L Burke; Mary J Tanga
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

9.  Chikungunya fever: a clinical and virological investigation of outpatients on Reunion Island, South-West Indian Ocean.

Authors:  Simon-Djamel Thiberville; Veronique Boisson; Jean Gaudart; Fabrice Simon; Antoine Flahault; Xavier de Lamballerie
Journal:  PLoS Negl Trop Dis       Date:  2013-01-17

Review 10.  Genomes to hits in silico - a country path today, a highway tomorrow: a case study of chikungunya.

Authors:  Anjali Soni; Khushhali M Pandey; Pratima Ray; B Jayaram
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.